Program for Camurus’ Capital Markets and R&D Day 14 December 2016

Lund, Sweden — Camurus AB (Nasdaq Stockholm; CAMX) today announces the program for the upcoming Capital Markets Day on 14th December in Stockholm.

Time: Wednesday 14 December, 1.30pm – 5.00pm CET
Venue: IVA Conference Center, Grev Turegatan 16, Stockholm
Invitation for: Institutional investors, analysts and media

Registration for investors, analysts and journalists
To participate, please register no later than 9 December at; CMD@camurus.com

A detailed program can be accessed below or on Camurus website www.camurus.com.

For more information please contact:
ir@camurus.com

Camurus
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com

The information was submitted for publication at 4.00 p.m. CET on 25 November 2016.